Saracatinib (AZD0530): Precision Src/Abl Kinase Inhibitor...
2026-02-10
Saracatinib (AZD0530) delivers nanomolar potency as a dual Src/Abl kinase inhibitor, enabling rigorous studies of cancer cell proliferation, migration, and key signaling pathways. Its robust performance in both oncology and emerging neurobiological models provides researchers with a versatile, data-backed tool for dissecting complex disease mechanisms. Leverage APExBIO’s trusted Saracatinib (A2133) for reproducible, hypothesis-driven workflows.
MOG (35-55): Benchmark Peptide for Experimental Autoimmun...
2026-02-09
MOG (35-55) is a validated myelin oligodendrocyte glycoprotein peptide used as a primary experimental autoimmune encephalomyelitis inducer in multiple sclerosis research. This dossier details its mechanism, benchmarks, and integration into neuroinflammation assays, underscoring its reproducibility and translational relevance.
Necrostatin 2: Advanced Insights into RIPK2-Mediated Necr...
2026-02-08
Explore the molecular intricacies of Necrostatin 2 as a leading RIPK2 kinase inhibitor for programmed necrotic cell death research. This article delivers unique scientific depth, including its emerging relevance in membrane lipid remodeling and future therapeutic strategies.
H-89: Precision PKA Inhibition for Metabolic and Osteogen...
2026-02-07
Discover how the selective cAMP-dependent protein kinase inhibitor H-89 enables advanced dissection of cAMP signaling in bone metabolism, metabolic rewiring, and disease models. This article uniquely explores H-89’s role at the intersection of PKA inhibition and cellular metabolic control, offering insights beyond standard signal transduction studies.
Amyloid Beta-Peptide (1-40) (human): Optimizing Alzheimer...
2026-02-07
Amyloid Beta-Peptide (1-40) (human) from APExBIO sets the standard for modeling amyloid aggregation, neurotoxicity, and microglial modulation in Alzheimer’s research. Unlock advanced experimental workflows, practical troubleshooting tips, and translational use-cases that maximize reproducibility and data confidence.
Biotin Azide (A8013): Precision Biotinylation for Click C...
2026-02-06
Biotin Azide is a high-purity biotinylation reagent for click chemistry, enabling selective and efficient labeling of alkynylated biomolecules for detection and affinity workflows in molecular biology. Its unique compatibility with copper-catalyzed azide-alkyne cycloaddition ensures robust, bio-orthogonal conjugation, facilitating downstream applications such as affinity purification and imaging. APExBIO’s Biotin Azide (A8013) sets industry benchmarks for purity and reproducibility.
Calpain Inhibitor I (ALLN): Mechanism, Evidence, and Work...
2026-02-06
Calpain Inhibitor I (ALLN) is a potent, cell-permeable calpain and cathepsin inhibitor used in apoptosis assay and inflammation research. This article provides atomic, verifiable facts about ALLN’s mechanism of action, application limits, and integration into high-content workflows. It extends existing knowledge by providing updated benchmarks and clarifying misconceptions critical for robust experimental design.
MHY1485: mTOR Activator for Autophagy Assays and Disease ...
2026-02-05
MHY1485 is the gold standard mTOR activator and autophagy inhibitor, offering researchers precise control over the mTOR signaling pathway and autophagic flux. Its distinct mechanism—autophagy inhibition by suppression of autophagosome-lysosome fusion—empowers advanced cell biology, ovarian follicle development, and disease modeling studies.
BIIE 0246: Selective Y2 Receptor Antagonist for Neuroscie...
2026-02-05
BIIE 0246 empowers researchers to precisely dissect neuropeptide Y Y2 receptor signaling, unlocking new insights into feeding behavior, anxiety modulation, and the adipose-neural axis. Its unmatched selectivity, nanomolar affinity, and robust presynaptic inhibitory effect blockade make it indispensable for advanced neuroscience and cardiometabolic workflows.
DOT1L Inhibitor EPZ-5676: Precision Epigenetic Targeting ...
2026-02-04
Explore the strategic and mechanistic frontiers of epigenetic regulation in cancer with DOT1L inhibitor EPZ-5676. This thought-leadership article provides translational researchers with an in-depth narrative on the molecular rationale, experimental validation, and clinical potential of EPZ-5676, while highlighting its unique role in advancing histone methyltransferase inhibition assays and MLL-rearranged leukemia treatment. By integrating evidence from peer-reviewed studies and related content assets, this piece offers actionable guidance for leveraging EPZ-5676 in innovative cancer research programs.
Precision Control of BMP Signaling: DMH1 as a Strategic L...
2026-02-04
This thought-leadership article explores how DMH1, a selective BMP type I receptor inhibitor, empowers translational researchers to precisely modulate cellular fate in organoid engineering and non-small cell lung cancer (NSCLC) research. By integrating mechanistic insights, recent advances in tunable organoid systems, and strategic guidance, this piece situates DMH1 as a pivotal tool for next-generation tissue modeling and targeted tumor suppression.
Rotenone (SKU B5462): Reliable Tool for Mitochondrial Dys...
2026-02-03
This comprehensive guide explores how Rotenone (SKU B5462) from APExBIO addresses real-world laboratory challenges in mitochondrial dysfunction, cell viability, and autophagy research. Integrating scenario-based Q&As, validated protocols, and up-to-date literature, the article demonstrates how Rotenone enables reproducible, data-driven workflows for neurodegenerative disease modeling and mechanistic pathway studies.
ONX-0914 (PR-957): Scenario-Driven Solutions for Reliable...
2026-02-03
This article offers biomedical researchers and lab scientists an evidence-based, scenario-driven guide to overcoming key challenges in immunoproteasome-targeted assays with ONX-0914 (PR-957) (SKU A4011). Leveraging validated protocols and quantitative literature, it demonstrates how APExBIO’s ONX-0914 enables reproducible cytokine modulation, optimized cell viability workflows, and robust disease modeling. Practical Q&A blocks equip users to navigate experimental design, data interpretation, and vendor selection with confidence.
Eltanexor (KPT-8602): Second-Generation XPO1 Inhibitor fo...
2026-02-02
Eltanexor (KPT-8602) is a potent, orally bioavailable second-generation XPO1 inhibitor for advanced cancer research. It demonstrates robust nuclear export inhibition, superior tolerability to earlier compounds, and significant efficacy in preclinical models of hematological and solid tumors. This article details its mechanism, evidence, and optimal laboratory integration.
Optimizing Transcriptional Assays: α-Amanitin (SKU A4548)...
2026-02-01
This article provides an evidence-driven roadmap for leveraging α-Amanitin (SKU A4548) in sensitive cell-based and transcriptional assays. Drawing on practical laboratory scenarios, quantitative data, and recent literature, we clarify best practices for RNA polymerase II inhibition, protocol optimization, and product selection. APExBIO’s α-Amanitin is highlighted for its reproducibility and validated purity, offering actionable insights for biomedical researchers.
457 records 29/31 page Previous Next First page 上5页 2627282930 下5页 Last page